Welcome to our dedicated page for Abvc Biopharma SEC filings (Ticker: ABVC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ABVC BioPharma, Inc. (NASDAQ: ABVC) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including annual and quarterly reports and current reports on Form 8-K. As a clinical-stage biopharmaceutical company focused on oncology/hematology, central nervous system disorders, and ophthalmology, ABVC uses these filings to describe its pipeline, licensing arrangements, financing activities, and other material events.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, readers can review management’s discussion of operating results, R&D spending, and the status of key programs such as CNS candidates for major depressive disorder and ADHD, oncology assets with US FDA-approved INDs, and the Vitargus® vitreous substitute device. These reports also outline intellectual property holdings, including patents on Polygala extract-based therapies and ophthalmology technologies, and discuss collaboration structures with partners like AiBtl BioPharma Inc., ForSeeCon Eye Corporation, and OncoX BioPharma Inc.
Current reports on Form 8-K capture specific events, such as licensing agreements, financing transactions, changes in the independent registered public accounting firm, and updates on Nasdaq listing compliance. They also reference press releases announcing financial results for particular quarters, providing timely insight into revenue from services and licensing payments, as well as changes in stockholders’ equity and debt arrangements.
On Stock Titan, ABVC filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify items related to clinical progress, licensing economics, or capital structure. Real-time updates from the SEC’s EDGAR system ensure that new 10-K, 10-Q, and 8-K filings, along with any other relevant forms, appear promptly. Users can also monitor disclosures that may relate to executive or director equity awards and other equity incentive matters as described in ABVC’s filings.
ABVC BioPharma received an amended Schedule 13G filed by Lind Global Fund II LP, Lind Global Partners II LLC and Jeff Easton reporting beneficial ownership of 557,143 shares, equal to 3.2% of the outstanding common stock. The position is composed of 0 currently held common shares, 500,000 B Warrants and 57,143 shares issuable under convertible securities. Lind Global Partners II LLC and Mr. Easton report sole voting and dispositive power over the position.
The filing includes a certification that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.
ABVC BioPharma has filed a Form S-8 registration statement to register an additional 2,515,989 shares of common stock under its Second Amended and Restated 2016 Equity Incentive Plan. The company's authorized capital consists of 100 million shares of common stock and 20 million shares of preferred stock, both with $0.001 par value.
Key details:
- Currently has 16,773,261 shares of common stock outstanding
- No preferred stock currently outstanding
- Classified as a non-accelerated filer and smaller reporting company
- Led by CEO Dr. Uttam Patil, who also serves as Interim CFO
The filing includes comprehensive indemnification provisions for directors and officers under Nevada law (NRS 78.138), protecting them against liability except in cases of intentional misconduct, fraud, or knowing violations of law. The registration statement incorporates by reference various SEC filings from 2025, including annual, quarterly, and current reports.